Management of Patients With Giant Cell Myocarditis: JACC Review Topic of the Week.
J Am Coll Cardiol
; 77(8): 1122-1134, 2021 03 02.
Article
in En
| MEDLINE
| ID: mdl-33632487
ABSTRACT
Giant cell myocarditis is a rare, often rapidly progressive and potentially fatal, disease due to T-cell lymphocyte-mediated inflammation of the myocardium that typically affects young and middle-aged adults. Frequently, the disease course is marked by acute heart failure, cardiogenic shock, intractable ventricular arrhythmias, and/or heart block. Diagnosis is often difficult due to its varied clinical presentation and overlap with other cardiovascular conditions. Although cardiac biomarkers and multimodality imaging are often used as initial diagnostic tests, endomyocardial biopsy is required for definitive diagnosis. Combination immunosuppressive therapy, along with guideline-directed medical therapy, has led to a paradigm shift in the management of giant cell myocarditis resulting in an improvement in overall and transplant-free survival. Early diagnosis and prompt management can decrease the risk of transplantation or death, which remain common in patients who present with cardiogenic shock.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Giant Cells
/
Myocarditis
Type of study:
Diagnostic_studies
/
Guideline
/
Screening_studies
Limits:
Humans
Language:
En
Journal:
J Am Coll Cardiol
Year:
2021
Document type:
Article
Affiliation country:
United States